FAA Reviews Cannabis Standards for Pilot Medical Certification

FAA Review Scope and Timeline

The FAA has initiated an internal review of cannabis-use protocols affecting airman medical certificates, though no formal Notice of Proposed Rulemaking has been published. According to Aero-News.net, the review follows mounting pressure from aviation medical examiners and pilot advocacy groups requesting clarity on detection windows, metabolite thresholds, and state-legal use disclosures.

No timeline yet. The agency hasn't announced when it'll complete the review or issue guidance. Current regulations under 14 CFR Part 67 disqualify applicants who use substances prohibited under federal law, including cannabis classified as Schedule I under the Controlled Substances Act.

Current Federal Aviation Regulations on Cannabis

Under 14 CFR §67.307, any "substance dependence" or "substance abuse" disqualifies an applicant for a first-class, second-class, or third-class medical certificate. The regulation doesn't distinguish between state-legal and illegal use. Aviation Medical Examiners (AMEs) are required to report any cannabis use disclosed during the medical examination process.

Pilots who test positive for THC metabolites face certificate suspension or revocation under 14 CFR §61.15. The FAA's drug-testing program uses a 50 ng/mL cutoff for THC-COOH in urine, a threshold that can detect use weeks after consumption in regular users.

Key regulatory prohibitions include:

• Zero tolerance for any cannabis use, regardless of state law
• Mandatory reporting of cannabis use on FAA Form 8500-8 (MedXPress)
• Automatic disqualification for substance-abuse history without documented abstinence and evaluation
• Random drug testing for commercial pilots under 14 CFR Part 120

State Legalization Collision with Federal Aviation Law

Thirty-eight states have legalized medical or adult-use cannabis, creating a regulatory conflict for pilots residing in legal states. State laws don't matter here. The FAA has repeatedly stated that state legalization doesn't affect federal aviation safety standards. A 2019 agency memo reaffirmed that "marijuana remains a drug listed in Schedule I" and use "is not acceptable for pilots, controllers, mechanics, or others who perform safety-sensitive functions."

Pilots who hold state-issued medical cannabis cards face particular scrutiny. Disclosure of a medical cannabis card on Form 8500-8 typically results in medical certificate denial pending a substance-abuse evaluation and documented abstinence period, often 12-24 months.

Detection Windows and Metabolite Persistence Issues

THC metabolites can remain detectable in urine for 30 days or longer in frequent users, creating enforcement complications when pilots cease use to comply with FAA standards. The agency's 50 ng/mL cutoff for THC-COOH doesn't distinguish between recent impairment and residual metabolites from weeks-old consumption.

Aviation medical examiners have requested FAA guidance on:

• Acceptable abstinence periods before medical certification
• Alternative testing methods (blood, saliva) with shorter detection windows
• Metabolite thresholds that correlate with actual impairment versus historical use
• Protocols for one-time versus habitual use disclosures

Right now, the agency requires pilots with any cannabis-use history to undergo neuropsychological evaluation and provide negative urine screens for at least six months before medical reconsideration.

Industry and Advocacy Group Pressure

The Aircraft Owners and Pilots Association and other aviation groups have submitted comments urging the FAA to align cannabis policies with evolving state laws and scientific evidence on impairment duration. A 2025 AOPA survey found that 14% of private pilots reported state-legal cannabis use, though most didn't disclose it on medical applications due to fear of certificate loss.

The National Air Traffic Controllers Association has similarly called for policy updates, noting that controllers face identical zero-tolerance standards under 14 CFR Part 65. Industry groups argue that blanket prohibitions may incentivize non-disclosure and reduce safety by deterring pilots from seeking medical cannabis treatment for conditions like chronic pain or PTSD.

For full background on this story, see the CannIntel topic hub on FAA Cannabis Pilot Standards.

Potential Policy Outcomes and Compliance Implications

The FAA could issue updated guidance on cannabis-use protocols without amending Part 67 regulations, similar to its 2019 CBD clarification memo. Possible outcomes include revised abstinence-period recommendations, updated metabolite thresholds, or a tiered approach distinguishing one-time use from chronic dependence.

Still, any substantive regulatory change would require the agency to reconcile federal aviation safety mandates with the Controlled Substances Act's Schedule I classification of cannabis. Until DEA rescheduling or congressional action removes cannabis from Schedule I, the FAA's legal authority to permit any use remains constrained.

Pilots should monitor FAA guidance updates and consult aviation medical examiners before disclosing any cannabis use. Watch for this: whether the agency publishes formal guidance or proceeds to NPRM rulemaking in Q4 2026.